文献速递免疫规划传染病防控与疫情报告

13价肺炎球菌结合疫苗对儿童肺炎球菌性脑膜炎的影响

Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children.
PubMed 文献 · Vaccine · 2017-07-12

前瞻性监测研究纳入马德里地区27家医院15岁以下确诊肺炎球菌性脑膜炎患儿,比较7价与13价肺炎球菌结合疫苗常规免疫时期。13价疫苗时期发病率较7价时期下降62%(95%CI:45-75%),主要源自19A血清型病例减少83%(95%CI:30-96%),对头孢噻肟不敏感菌株从27%降至8%(p=0.02),但病死率与不良结局率两期相似。

要点

  • 13价肺炎球菌结合疫苗时期肺炎球菌性脑膜炎发病率较7价时期下降62%(95%CI:45-75%)。
  • 19A血清型所致病例减少83%(95%CI:30-96%),对头孢噻肟不敏感菌株从27%降至8%(p=0.02)。
  • 两期病死率均为5%,不良结局(死亡或神经系统后遗症)发生率27%,两期相似。

核心结论

  • 接种13价肺炎球菌结合疫苗降低了15岁以下儿童肺炎球菌性脑膜炎发病率,对头孢噻肟耐药菌株接近消除,但疾病负担(不良结局率)未见改变,且观察到发病年龄略有升高。

研究设计与样本

  • 前瞻性监测研究,纳入2007年至2015年马德里地区27家医院15岁以下确诊肺炎球菌性脑膜炎患儿,共104例,其中7价肺炎球菌结合疫苗常规免疫时期(2007年5月至2010年4月)63例,13价肺炎球菌结合疫苗免疫时期(2010年5月至2015年4月)41例。

主要发现

  • 13价疫苗时期较7价疫苗时期肺炎球菌性脑膜炎发病率下降62%(95%CI:45-75%),从每10万居民2.19例降至0.81例(p=0.0001)。
  • 发病率下降主要源自19A血清型病例减少83%(95%CI:30-96%)。
  • 对头孢噻肟不敏感(MIC>0.5μg/L)菌株从27%降至8%(p=0.02)。
  • 患者平均年龄从28.7月龄升至38.5月龄(p<0.05)。
  • 两期合计病死率5%,不良结局(死亡或神经系统后遗症)发生于27%的患者,两期发生率相似;研究期间未观察到13价肺炎球菌结合疫苗未覆盖血清型所致脑膜炎增加。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. METHODS: Children younger than 15years of age attending 27 hospitals in the Region of Madrid with confirmed pneumococcal meningitis were identified in a prospective surveillance study, from 2007 to 2015. Clinical data, neurological sequelae, pneumococcal vaccination status, serotyping and antibiotic susceptibility were recorded. RESULTS: One hundred and four cases of pneumococcal meningitis were identified, 63 during the period of routine 7-valent pneumococcal conjugate vaccine immunisation (May 2007-April 2010) and 41 during the period of 13-valent pneumococcal conjugate vaccine immunisation (May 2010-April 2015). When both periods were compared, a 62% (95% CI: 45-75%) decrease in the incidence of pneumococcal meningitis was observed, from 2.19 cases per 100,000 inhabitants in the PCV7 period to 0.81 per 100,000 inhabitants in the PCV13 period (p=0.0001), mainly due to an 83% (95% CI: 30-96%) reduction in cases caused by serotype 19A. Isolates not susceptible to cefotaxime (MIC>0.5μg/L) decreased from 27% to 8%, (p=0.02). Mean patient ages rose from 28.7months to 38.5months (p<0.05). Case fatality rate across both periods was 5%. An unfavourable outcome (death or neurological sequelae) occurred in 27% of patients, while the rate was similar in both periods. There was no increase in meningitis caused by pneumococcal serotypes not included in 13-valent pneumococcal conjugate vaccine throughout the years of the study. CONCLUSIONS: Immunisation with 13-valent pneumococcal conjugate vaccine has reduced the rate of pneumococcal meningitis in children less than 15years, with a near-elimination of cefotaxime-resistant isolates, but morbidity has remained unchanged. A shift of pneumococcal meningitis towards slightly higher age groups was also observed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ruiz-Contreras J, Picazo J, Casado-Flores J, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Vaccine. 2017. PMID: 28711388. doi:10.1016/j.vaccine.2017.06.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。